Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes
- PMID: 36687427
- PMCID: PMC9845885
- DOI: 10.3389/fmed.2022.962337
Severe hypoglycemia in patients with liver cirrhosis and type 2 diabetes
Abstract
Introduction: Advanced liver disease with massive liver damage may affect the metabolism of hypoglycemic agents and increase the risk of hypoglycemia. We conduct this research to compare the risk of severe hypoglycemia between patients with type 2 diabetes, with and without compensated liver cirrhosis.
Methods: From Taiwan's National Health Insurance Research Database, we identified persons with type 2 diabetes with cirrhosis (n = 18,209) and without cirrhosis (n = 538,510) from January 1, 2000, to December 31, 2010. Cox proportional hazards models were adopted to assess risks of all-cause mortality and severe hypoglycemia.
Results: The mean follow-up period of this study was 3.7 years. The incidence rates of death during follow-up were 26.54 and 2.75 per 1,000 patient-years [aHR 7.63 (6.70-8.70)] for patients with cirrhosis and without cirrhosis, respectively. The incidence rates of severe hypoglycemia during follow-up were 0.53 and 0.14 per 1,000 patient-years [aHR 2.74 (1.52-4.92)] for patients with and without cirrhosis, respectively. The subgroup analysis of hypoglycemia risks in patients with and without cirrhosis disclosed no significant interaction for variables such as age, sex, chronic kidney disease, sulfonylurea use, number of oral antidiabetic drugs, insulin, b-blocker, and fibrate.
Conclusion: This cohort study demonstrated that patients with type 2 diabetes and compensated cirrhosis showed a higher risk of mortality and severe hypoglycemia than those without liver cirrhosis.
Keywords: all-cause mortality; chronic kidney disease; hypoglycemic agents; liver cirrhosis; sulfonylurea.
Copyright © 2023 Yen, Hou, Liu, Hsu and Hwu.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures




Similar articles
-
Association between hypoglycemia and poor clinical outcomes in hospitalized non-diabetic patients with liver cirrhosis:- a narrative review.Front Med (Lausanne). 2025 May 16;12:1541471. doi: 10.3389/fmed.2025.1541471. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40454148 Free PMC article. Review.
-
Is insulin the preferred treatment in persons with type 2 diabetes and liver cirrhosis?BMC Gastroenterol. 2021 Jun 12;21(1):263. doi: 10.1186/s12876-021-01773-x. BMC Gastroenterol. 2021. PMID: 34118892 Free PMC article.
-
Metformin use and cirrhotic decompensation in patients with type 2 diabetes and liver cirrhosis.Br J Clin Pharmacol. 2022 Jan;88(1):311-322. doi: 10.1111/bcp.14970. Epub 2021 Jul 22. Br J Clin Pharmacol. 2022. PMID: 34198358 Free PMC article.
-
The Risk of Severe Hypoglycemia and Mortality in Patients With Type 2 Diabetes and Discharged With Acute Liver Injury.Diabetes Care. 2023 Jan 1;46(1):20-27. doi: 10.2337/dc22-1349. Diabetes Care. 2023. PMID: 36378550
-
Sulfonylureas may be useful for glycemic management in patients with diabetes and liver cirrhosis.PLoS One. 2020 Dec 14;15(12):e0243783. doi: 10.1371/journal.pone.0243783. eCollection 2020. PLoS One. 2020. PMID: 33315940 Free PMC article.
Cited by
-
From liver to hormones: The endocrine consequences of cirrhosis.World J Gastroenterol. 2024 Mar 7;30(9):1073-1095. doi: 10.3748/wjg.v30.i9.1073. World J Gastroenterol. 2024. PMID: 38577191 Free PMC article. Review.
-
Innovative Drugs First Implemented in Type 2 Diabetes Mellitus and Obesity and Their Effects on Metabolic Dysfunction-Associated Steatohepatitis (MASH)-Related Fibrosis and Cirrhosis.J Clin Med. 2025 Feb 7;14(4):1042. doi: 10.3390/jcm14041042. J Clin Med. 2025. PMID: 40004572 Free PMC article. Review.
-
Association between hypoglycemia and poor clinical outcomes in hospitalized non-diabetic patients with liver cirrhosis:- a narrative review.Front Med (Lausanne). 2025 May 16;12:1541471. doi: 10.3389/fmed.2025.1541471. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40454148 Free PMC article. Review.
-
The Fascinating Interplay between Growth Hormone, Insulin-Like Growth Factor-1, and Insulin.Endocrinol Metab (Seoul). 2024 Feb;39(1):83-89. doi: 10.3803/EnM.2024.101. Epub 2024 Jan 9. Endocrinol Metab (Seoul). 2024. PMID: 38192102 Free PMC article. Review.
-
Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.Front Endocrinol (Lausanne). 2024 Nov 21;15:1456195. doi: 10.3389/fendo.2024.1456195. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39665021 Free PMC article. Review.
References
-
- Cryer P. Hypoglycemia in Diabetes: Pathophysiology, Prevalence and Prevention. Alexandria, VA: American Diabetes Association; (2012). p. 37–125.
LinkOut - more resources
Full Text Sources